Update on coronary artery bioresorbable vascular scaffolds in percutaneous coronary revascularization

Coronary angioplasty was first introduced in 1977. From plain old balloon angioplasty to the introduction of bare metal stents in 1986 and dual antiplatelet therapy in 1992 to much more later on. Due to the unacceptable rate of stent restenosis, drug eluting stents (DES) were introduced in 2000....

Full description

Bibliographic Details
Main Authors: Nagi Azzi, Wassim Shatila
Format: Article
Language:English
Published: IMR (Innovative Medical Research) Press Limited 2021-03-01
Series:Reviews in Cardiovascular Medicine
Subjects:
Online Access:https://rcm.imrpress.com/fileup/2153-8174/PDF/1617068614798-1520393906.pdf
id doaj-1b132d1f6be1437494a92cb8677b4134
record_format Article
spelling doaj-1b132d1f6be1437494a92cb8677b41342021-04-01T09:19:29ZengIMR (Innovative Medical Research) Press LimitedReviews in Cardiovascular Medicine2153-81742021-03-0122113714510.31083/j.rcm.2021.01.2251617068614798-1520393906Update on coronary artery bioresorbable vascular scaffolds in percutaneous coronary revascularizationNagi Azzi0Wassim Shatila1Department of Cardiology, Lebanese American University - Rizk Hospital, 1100 Beirut, LebanonDepartment of Cardiology, Texas Heart Institute, Houston, TX 77030, USACoronary angioplasty was first introduced in 1977. From plain old balloon angioplasty to the introduction of bare metal stents in 1986 and dual antiplatelet therapy in 1992 to much more later on. Due to the unacceptable rate of stent restenosis, drug eluting stents (DES) were introduced in 2000. The first generation showed an increase in late stent thrombosis which led to the introduction of the second generation DES with biocompatible or biodegradable polymers and thinner platforms. However very late stent thrombosis and late restenosis might still pose problems in the latter. Furthermore, there has been major debate regarding the impact of long-term vessel caging on normal vasomotricity and long-term positive remodeling. To resolve these issues, the bioresorbable vascular scaffolds (BVS) were launched into the real world in 2011, showing promising initial results. Multiple randomized trials, meta-analyses, and registries were performed, mainly with the Absorb Bioresorbable Vascular Scaffold System (Abbott Vascular, Chicago, IL, USA). This new technology is hindered by certain features, such as the BVS radial strength, its strut thickness, and the inflammatory process related to scaffold degradation. Moreover, there is known data indicating higher thrombosis rate with the Absorb BVS compared with the new generation of DES, despite similar cardiovascular death. In this review, we discuss the clinical procedural and technical evidence on BVS, with emphasis on their clinical impact. We finally tackle the future directions on device and procedural improvement while asking: is the bioresorbable technology still the way to the future?https://rcm.imrpress.com/fileup/2153-8174/PDF/1617068614798-1520393906.pdfpercutaneous interventionsbioresorbable vascular scaffoldsoutcomes
collection DOAJ
language English
format Article
sources DOAJ
author Nagi Azzi
Wassim Shatila
spellingShingle Nagi Azzi
Wassim Shatila
Update on coronary artery bioresorbable vascular scaffolds in percutaneous coronary revascularization
Reviews in Cardiovascular Medicine
percutaneous interventions
bioresorbable vascular scaffolds
outcomes
author_facet Nagi Azzi
Wassim Shatila
author_sort Nagi Azzi
title Update on coronary artery bioresorbable vascular scaffolds in percutaneous coronary revascularization
title_short Update on coronary artery bioresorbable vascular scaffolds in percutaneous coronary revascularization
title_full Update on coronary artery bioresorbable vascular scaffolds in percutaneous coronary revascularization
title_fullStr Update on coronary artery bioresorbable vascular scaffolds in percutaneous coronary revascularization
title_full_unstemmed Update on coronary artery bioresorbable vascular scaffolds in percutaneous coronary revascularization
title_sort update on coronary artery bioresorbable vascular scaffolds in percutaneous coronary revascularization
publisher IMR (Innovative Medical Research) Press Limited
series Reviews in Cardiovascular Medicine
issn 2153-8174
publishDate 2021-03-01
description Coronary angioplasty was first introduced in 1977. From plain old balloon angioplasty to the introduction of bare metal stents in 1986 and dual antiplatelet therapy in 1992 to much more later on. Due to the unacceptable rate of stent restenosis, drug eluting stents (DES) were introduced in 2000. The first generation showed an increase in late stent thrombosis which led to the introduction of the second generation DES with biocompatible or biodegradable polymers and thinner platforms. However very late stent thrombosis and late restenosis might still pose problems in the latter. Furthermore, there has been major debate regarding the impact of long-term vessel caging on normal vasomotricity and long-term positive remodeling. To resolve these issues, the bioresorbable vascular scaffolds (BVS) were launched into the real world in 2011, showing promising initial results. Multiple randomized trials, meta-analyses, and registries were performed, mainly with the Absorb Bioresorbable Vascular Scaffold System (Abbott Vascular, Chicago, IL, USA). This new technology is hindered by certain features, such as the BVS radial strength, its strut thickness, and the inflammatory process related to scaffold degradation. Moreover, there is known data indicating higher thrombosis rate with the Absorb BVS compared with the new generation of DES, despite similar cardiovascular death. In this review, we discuss the clinical procedural and technical evidence on BVS, with emphasis on their clinical impact. We finally tackle the future directions on device and procedural improvement while asking: is the bioresorbable technology still the way to the future?
topic percutaneous interventions
bioresorbable vascular scaffolds
outcomes
url https://rcm.imrpress.com/fileup/2153-8174/PDF/1617068614798-1520393906.pdf
work_keys_str_mv AT nagiazzi updateoncoronaryarterybioresorbablevascularscaffoldsinpercutaneouscoronaryrevascularization
AT wassimshatila updateoncoronaryarterybioresorbablevascularscaffoldsinpercutaneouscoronaryrevascularization
_version_ 1724176573259579392